Indiana Department of Health

Long-term Care NEWSLETTER

LTC Newsletter 2021-37
August 4, 2021

LTC Update:

- **FDA – Emergency Use Authorization (EUA) for REGEN-COV2**

FDA – Emergency Use Authorization (EUA) for REGEN-COV2

The US FDA has issued emergency use authorization (EUA) to permit the emergency use of REGEN-COV2 (Casirivimab and Imdevimab) together for post exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19 including hospitalization and death. It is expected to be effective against circulating variants, including the Delta variant. It is not a substitute for vaccination against COVID-19 and is not authorized for pre-exposure prophylaxis.

- FDA authorizes REGEN-COV monoclonal antibody therapy for post exposure prophylaxis (prevention) for COVID-19
- Fact Sheet for Health Care Providers – EUA of REGEN-COV
- Fact Sheet for Patients, Parents and Caregivers – EUA of REGEN-COV
- Frequently Asked Questions on the EUA of REGEN-COV